A new CRISPR system recently published in Nature could change how we think about selectively eliminating cancer cells without touching healthy tissue. Instead of using the classic Cas9 to edit DNA, researchers have repurposed Cas12a2, an enzyme that first binds to a specific RNA sequence and then unleashes a wave of DNA destruction across the […]
Antibody–drug conjugates (ADCs) have transformed therapy in several malignancies, but in advanced prostate cancer they have mostly been evaluated for direct tumor cytotoxicity, with little attention to immune mechanisms that might underpin durable responses. A recent study introduces a new STEAP1‑targeted ADC platform built on vandortuzumab, an antibody directed at six‑transmembrane epithelial antigen of the […]
A huge international team has just completed the largest study ever on how our genes control the levels of proteins circulating in our blood. The work, led by researchers at Queen Mary University of London and the Berlin Institute of Health, brings together data from more than 78,000 people across 38 cohorts worldwide and has […]
GX-BP1, a bioPROTAC-based SOX2 degrader, selectively targets SOX2, an undruggable protein, for ubiquitin-proteasome elimination, overcoming limitations of prior inhibition strategies. In preclinical models, GX-BP1 monotherapy delivered approximately 70% tumor growth inhibition, while combinations with agents like carboplatin/paclitaxel achieved 87-96% inhibition and near-complete tumor suppression at optimal doses. Notably, GX-BP1 paired with osimertinib eradicated cancer stem […]
Prostate cancer treatments have hit a wall with castration-resistant cases, where tumors keep growing despite hormone blockers targeting the androgen receptor’s stable parts. A new study from University of British Columbia and BC Cancer researchers published on Nature cracks that open by hitting the receptor’s “undruggable” intrinsically disordered transactivation domain (NTD/TAD), the flexible region that […]
A new study in Nature Biotechnology describes a DNA-based drug system that can turn on only when it finds the right combination of markers on a cancer cell. This matters because many cancer drugs are powerful but also damage healthy tissue, so the main challenge is not only killing the tumor, but doing it with […]
Adoptive transfer of chimeric antigen receptor (CAR) T cells has worked well in some blood cancers, but it has been much less effective in solid tumors like prostate cancer. One reason is the strong cytokine release and strong immune suppression in the tumor area. A new study has designed a PSMA‑targeted CAR that uses CD16A, […]
For prostate cancer patients with low expression of PSMA or with neuroendocrine prostate cancer or NEPC (a population growing in size precisely because better treatments are forcing tumors to adapt), a new preclinical study offers a credible precision-targeted strategy: a radiotheranostic pair built on the CEACAM5 surface antigen that produced complete tumor responses in every […]
A new experimental compound, ITRI-148, may represent a meaningful shift in how advanced prostate cancer is treated, particularly in patients who develop resistance to current androgen receptor (AR)-targeted therapies. Resistance to drugs like enzalutamide is frequently driven by AR splice variants such as AR-V7, which lack the ligand-binding domain (LBD) targeted by existing therapies, allowing […]
A new generation of PSMA-targeted T-cell engagers is emerging with a clear goal: preserve the potency seen in hematologic malignancies while overcoming the safety and efficacy barriers that have limited success in solid tumors. A preclinical candidate, ProTCE-PSMA, presented ahead of IND filing in early 2026, illustrates how rapidly this field is evolving beyond first-generation […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy